Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
“These results, with early and lasting improvement in symptoms following a single administration of COMP360, are highly encouraging,” said Dr.
- “These results, with early and lasting improvement in symptoms following a single administration of COMP360, are highly encouraging,” said Dr.
- “These observations, even with a small, open-label study, suggest that COMP360 could provide a clinically meaningful benefit and substantially improve patient daily function and quality of life.
- The well tolerated safety profile for COMP360 in patients with PTSD, with no serious adverse events observed, advance our understanding of potential applications of COMP360.
- Compass previously announced 24-hour safety data from the study, which indicated that COMP360 was well-tolerated, with no treatment emergent serious adverse events.